Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning.

dc.contributor.author

Boelens, Jaap Jan

dc.contributor.author

Aldenhoven, Mieke

dc.contributor.author

Purtill, Duncan

dc.contributor.author

Ruggeri, Annalisa

dc.contributor.author

Defor, Todd

dc.contributor.author

Wynn, Robert

dc.contributor.author

Wraith, Ed

dc.contributor.author

Cavazzana-Calvo, Marina

dc.contributor.author

Rovelli, Attilio

dc.contributor.author

Fischer, Alain

dc.contributor.author

Tolar, Jakub

dc.contributor.author

Prasad, Vinod K

dc.contributor.author

Escolar, Maria

dc.contributor.author

Gluckman, Eliane

dc.contributor.author

O'Meara, Anne

dc.contributor.author

Orchard, Paul J

dc.contributor.author

Veys, Paul

dc.contributor.author

Eapen, Mary

dc.contributor.author

Kurtzberg, Joanne

dc.contributor.author

Rocha, Vanderson

dc.contributor.author

Eurocord

dc.contributor.author

Inborn Errors Working Party of European Blood and Marrow Transplant group

dc.contributor.author

Duke University Blood and Marrow Transplantation Program

dc.contributor.author

Centre for International Blood and Marrow Research

dc.date.accessioned

2022-03-23T20:45:10Z

dc.date.available

2022-03-23T20:45:10Z

dc.date.issued

2013-05

dc.date.updated

2022-03-23T20:45:10Z

dc.description.abstract

We report transplantation outcomes of 258 children with Hurler syndrome (HS) after a myeloablative conditioning regimen from 1995 to 2007. Median age at transplant was 16.7 months and median follow-up was 57 months. The cumulative incidence of neutrophil recovery at day 60 was 91%, acute graft-versus-host disease (GVHD) (grade II-IV) at day 100 was 25%, and chronic GVHD and 5 years was 16%. Overall survival and event-free survival (EFS) at 5 years were 74% and 63%, respectively. EFS after HLA-matched sibling donor (MSD) and 6/6 matched unrelated cord blood (CB) donor were similar at 81%, 66% after 10/10 HLA-matched unrelated donor (UD), and 68% after 5/6 matched CB donor. EFS was lower after transplantation in 4/6 matched unrelated CB (UCB) (57%; P = .031) and HLA-mismatched UD (41%; P = .007). Full-donor chimerism (P = .039) and normal enzyme levels (P = .007) were higher after CB transplantation (92% and 98%, respectively) compared with the other grafts sources (69% and 59%, respectively). In conclusion, results of allogeneic transplantation for HS are encouraging, with similar EFS rates after MSD, 6/6 matched UCB, 5/6 UCB, and 10/10 matched UD. The use of mismatched UD and 4/6 matched UCB was associated with lower EFS.

dc.identifier

S0006-4971(20)58688-6

dc.identifier.issn

0006-4971

dc.identifier.issn

1528-0020

dc.identifier.uri

https://hdl.handle.net/10161/24700

dc.language

eng

dc.publisher

American Society of Hematology

dc.relation.ispartof

Blood

dc.relation.isversionof

10.1182/blood-2012-09-455238

dc.subject

Eurocord

dc.subject

Inborn Errors Working Party of European Blood and Marrow Transplant group

dc.subject

Duke University Blood and Marrow Transplantation Program

dc.subject

Centre for International Blood and Marrow Research

dc.subject

Hematopoietic Stem Cells

dc.subject

Humans

dc.subject

Mucopolysaccharidosis I

dc.subject

Myeloablative Agonists

dc.subject

Histocompatibility Testing

dc.subject

Treatment Outcome

dc.subject

Transplantation Conditioning

dc.subject

Hematopoietic Stem Cell Transplantation

dc.subject

Retrospective Studies

dc.subject

Adolescent

dc.subject

Child

dc.subject

Child, Preschool

dc.subject

Infant

dc.subject

Tissue Donors

dc.subject

Tissue and Organ Procurement

dc.subject

Female

dc.subject

Male

dc.subject

Young Adult

dc.title

Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning.

dc.type

Journal article

duke.contributor.orcid

Kurtzberg, Joanne|0000-0002-3370-0703

pubs.begin-page

3981

pubs.end-page

3987

pubs.issue

19

pubs.organisational-group

Duke

pubs.organisational-group

School of Medicine

pubs.organisational-group

Faculty

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Pathology

pubs.organisational-group

Pediatrics

pubs.organisational-group

Pediatrics, Hematology-Oncology

pubs.organisational-group

Duke Cancer Institute

pubs.organisational-group

Institutes and Provost's Academic Units

pubs.organisational-group

Initiatives

pubs.organisational-group

Duke Innovation & Entrepreneurship

pubs.organisational-group

Pediatrics, Transplant and Cellular Therapy

pubs.publication-status

Published

pubs.volume

121

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
p263 Boelens.pdf
Size:
666.47 KB
Format:
Adobe Portable Document Format
Description:
Published version